Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Merck and Owkin collaborate to develop AI-powered diagnostics for cancer

The companies aim to develop a pre-screening test to improve MSI-H testing for cancer

- PMLiVE

Hanover Communications promotes Emma Gorton as managing director

Gorton was previously deputy managing director of Hanover Health

- PMLiVE

Preventing strategic drift: aligning teams for a successful pharma product launch

By Adam Boucher

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

Newel Health launches study of digital therapeutic for Parkinson’s disease

The Soturi app is designed to optimise personalised treatment plans for patients

- PMLiVE

What does the changing social media landscape mean for pharma?

By Federico Marchisio

- PMLiVE

Making an Impact at ASH 2023

Medscape has left behind the sunny skies of San Deigo, having attended their final conference of the year at the ASH annual meeting.The team wrapped up the year with a...

Medscape Education

- PMLiVE

FDA establishes advisory committee for genetic metabolic disease treatments

The committee will evaluate the potential benefits and risks of new therapies for diagnosis, prevention and treatment

EU flag

CHMP recommends gene therapy for beta thalassemia and sickle cell disease

If approved, Casgevy will be the only genetic therapy in the EU to treat these conditions

- PMLiVE

EC, HMA and EMA publish first version of Union list of critical medicines

The established list aims to prevent potential future shortages of critical medicines in the EU

- PMLiVE

Harnessing the power of PR to boost marketing communications

By Gurjit Chahal

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links